Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5204954
Max Phase: Preclinical
Molecular Formula: C43H44F3N11O7
Molecular Weight: 883.89
Associated Items:
ID: ALA5204954
Max Phase: Preclinical
Molecular Formula: C43H44F3N11O7
Molecular Weight: 883.89
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CC(=O)NCCNc5cccc6c5C(=O)N(C5CCC(=O)N(C)C5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1
Standard InChI: InChI=1S/C43H44F3N11O7/c1-4-34(58)50-25-7-5-8-26(21-25)51-38-29(43(44,45)46)23-49-42(53-38)52-30-12-11-27(22-33(30)64-3)56-19-17-55(18-20-56)24-35(59)48-16-15-47-31-10-6-9-28-37(31)41(63)57(39(28)61)32-13-14-36(60)54(2)40(32)62/h4-12,21-23,32,47H,1,13-20,24H2,2-3H3,(H,48,59)(H,50,58)(H2,49,51,52,53)
Standard InChI Key: BZXSDSVDQKWSGO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 883.89 | Molecular Weight (Monoisotopic): 883.3377 | AlogP: 4.21 | #Rotatable Bonds: 15 |
Polar Surface Area: 210.54 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.84 | CX Basic pKa: 6.36 | CX LogP: 3.96 | CX LogD: 3.92 |
Aromatic Rings: 4 | Heavy Atoms: 64 | QED Weighted: 0.06 | Np Likeness Score: -1.30 |
1. Li Q, Guo Q, Wang S, Wan S, Li Z, Zhang J, Wu X.. (2022) Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686., 238 [PMID:35594654] [10.1016/j.ejmech.2022.114455] |
Source(1):